Blogs
- Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics
- A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report
- ‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout
- Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect
- The Psychedelic Practitioner Issue 5: Groups in Practice
- Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities
- May 2026 Psychedelic Bill Roundup
- Field Notes #2: Dispatches from London and the Netherlands
- Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial
- A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry
- Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race
- Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval
- Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future
- “If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics
- Q4 2025: Oregon Psilocybin Services Update
Magazines
- Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics
- A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report
- ‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout
- Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect
- The Psychedelic Practitioner Issue 5: Groups in Practice
- Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities
- May 2026 Psychedelic Bill Roundup
- Field Notes #2: Dispatches from London and the Netherlands
- Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial
- A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry
- Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race
- Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval
- Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future
- “If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics
- Q4 2025: Oregon Psilocybin Services Update
Record Labels
- Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics
- A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report
- ‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout
- Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect
- The Psychedelic Practitioner Issue 5: Groups in Practice
- Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities
- May 2026 Psychedelic Bill Roundup
- Field Notes #2: Dispatches from London and the Netherlands
- Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial
- A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry
- Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race
- Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval
- Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future
- “If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics
- Q4 2025: Oregon Psilocybin Services Update
News stories about record stores
- Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics
- A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report
- ‘A Sea Change’, With Caveats: A Closer Look at Definium’s Phase 3 LSD for MDD Readout
- Breaking: Definium Lands Positive Phase 3, LSD Candidate Shows Strong Antidepressant Effect
- The Psychedelic Practitioner Issue 5: Groups in Practice
- Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on the First Patients, Payers and Practicalities
- May 2026 Psychedelic Bill Roundup
- Field Notes #2: Dispatches from London and the Netherlands
- Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA Therapy Study Launches; Australia Loosens Psychedelics Access Regulations; VA Launches “New” MDMA Trial
- A Dispatch from APA’s Annual Meeting: Psychedelics Return at an Awkward Moment for American Psychiatry
- Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race
- Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval
- Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future
- “If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics
- Q4 2025: Oregon Psilocybin Services Update